Dextroamphetamine - Amphetamine ER Solicitation
ID: SPE2D2-25-R-0013Type: Solicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)
Timeline
    Description

    The Defense Logistics Agency (DLA) is soliciting proposals for the supply of Dextroamphetamine-Amphetamine ER capsules, with a contract duration of five years. The procurement involves various dosages, including 5 MG, 10 MG, 15 MG, 20 MG, 25 MG, and 30 MG, with estimated quantities of 7,915 units required for the base year and each of the four option years. This initiative is crucial for maintaining a consistent supply of essential medications within the federal healthcare system. Interested vendors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by June 27, 2025, and are encouraged to contact Nancy Fernandez or Catherine Gilbert for further information.

    Point(s) of Contact
    Files
    Title
    Posted
    The document is an amendment to a government solicitation for a federal contract (Contract ID SPE2D225R0013) issued by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain. The main purpose of this amendment is to announce the extension of the solicitation closing date to June 17, 2025, at 3:00 PM EDT. All other terms and conditions of the contract remain unchanged. It instructs contractors on how to acknowledge receipt of the amendment, which can be done either by acknowledging it on offer copies or through a separate letter or telegram referencing the solicitation. The amendment also emphasizes the importance of timely acknowledgment to avoid rejection of offers. The document adheres to federal procurement protocols, ensuring clarity and transparency in the solicitation process.
    This document is an amendment to a solicitation for contract SPE2D225R0013, issued on May 1, 2025. The primary purpose of the amendment is to correct a typographical error in item line number five and to confirm that the quantity for both the base and option years is 12,094. Furthermore, the closing date for the solicitation has been extended to June 27, 2025, at 3:00 PM. Vendors are required to acknowledge receipt of this amendment, and offers must be modified, if necessary, before the specified deadline. The amendment retains all other terms and conditions of the original solicitation unchanged. An updated schedule of supplies is attached to the document for further clarification. This amendment demonstrates the government's procedural adherence to necessary modifications of procurement processes, ensuring clarity in contractual obligations and deadlines.
    The document consists of fragmented and corrupted text, making it challenging to extract a coherent summary. However, the overarching theme appears to relate to federal government RFPs (Requests for Proposals), federal grants, and state and local RFPs. The purpose of these RFPs and grants typically involves soliciting proposals for various governmental projects or initiatives, ensuring that funding is allocated to qualified applicants. Key points suggest that attention is given to compliance, safety standards, and the necessary procedures involved in project execution. These aspects are critical for effective project management and regulatory adherence in government-funded activities. The document's structure seems disrupted, with heavy distortion affecting readability and comprehension, yet it is clear that these RFPs are crucial for fostering collaboration between government entities and service providers, contributing to public sector functionality and infrastructure improvements. Overall, the content promotes transparency, efficiency, and accountability in government processes, emphasizing the procurement standards expected in submissions for funding opportunities.
    The document is a solicitation (SPE2D2-25-R-0013) from the Defense Logistics Agency, outlining terms for a contract to supply various dosages of Dextroamphetamine-Amphetamine ER capsules over a span of five years. Key sections include submission instructions, contract clauses, and details on compliance with federal regulations. Offers must be submitted electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by June 3, 2025. Additionally, it mandates that large businesses provide a subcontracting plan and emphasizes adherence to ethical codes in federal contracting. The solicitation also includes various government clauses that contractors must follow, including those governing child labor, whistleblower protections, and subcontracting limits. Significant emphasis is placed on the prohibition of certain telecommunications equipment linked to national security concerns. Overall, the solicitation reflects the government's commitment to transparency, ethical conduct, and compliance with federal contracting standards while providing necessary pharmaceuticals. This solicitation serves as an essential framework for vendors aiming to engage with government procurement processes effectively.
    The document outlines a federal Request for Proposal (RFP) concerning the procurement of various dosages of Dextroamphetamine-Amphetamine ER capsules, specifying quantities, unit prices, and the National Drug Code (NDC) for each product. It lists six different dosage strengths—5 MG, 10 MG, 15 MG, 20 MG, 25 MG, and 30 MG—each requiring an estimated quantity of 7,915 units for a base year and four subsequent option years. The document designates these estimates as potential requirements, adhering to Federal Acquisition Regulation (FAR) 52.216-21, which pertains to requirements contracts. Each item is recorded as a bottle (BTL) containing 100 capsules. The RFP's structure emphasizes the importance of accurately estimating supply needs over the proposed five-year period, guiding prospective contractors in formulating competitive bids. This initiative reflects government efforts in maintaining a consistent supply of essential medications in alignment with federal procurement practices.
    Lifecycle
    Title
    Type
    Similar Opportunities
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Trazodone - Solicitation
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting offers for Trazodone HCL tablets in various dosages and bottle counts. This procurement aims to fulfill substantial pharmaceutical supply needs, emphasizing compliance with technical and quality requirements as outlined in the solicitation documents. The solicitation, identified as SPE2D2-26-R-0003, mandates electronic submissions via the Defense Logistics Agency Internet Bid Board System (DIBBS) by December 12, 2025, at 3:00 PM EST, with no alternative submission methods accepted. Interested parties can reach out to Nancy Fernandez at nancy.fernandez@dla.mil or Jason Wray at jason.wray@dla.mil for further inquiries.
    Sertraline Tablets
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting offers for the procurement of Sertraline Tablets in 25MG, 50MG, and 100MG dosages, with various bottle counts required over a base year and four option years. This solicitation, identified as SPE2D2-26-R-0002, is critical for ensuring the availability of this essential pharmaceutical, which is commonly used to treat depression and anxiety disorders among military personnel. Interested contractors must submit their offers electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by the extended deadline of December 17, 2025, at 3:00 PM EST, and are encouraged to contact Christopher Newman or Jason Wray for further inquiries regarding the solicitation.
    Ondansetron Orally Disintegrating Tablets
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Ondansetron Orally Disintegrating Tablets (ODT), specifically 4 MG and 8 MG tablets in various count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which are critical for treating nausea and vomiting in patients, and will be available for purchase by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in September 2025, although the DLA reserves the right to issue it earlier or later. Interested parties should direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or call 445-737-0713, and are encouraged to set up automated notifications for any changes to the solicitation through the DLA Bid Board System and Sam.Gov.
    Metformin HCL
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    Rabeprazole Sodium Delayed Release Tablets
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    6505--Carbidopa Levodopa Immediate Release (IR) Tablets
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Carbidopa Levodopa Immediate Release (IR) Tablets, aimed at ensuring a reliable supply for various federal health care entities, including the VA, Department of Defense (DoD), and Bureau of Prisons (BOP). The procurement will involve awarding a single contract for an initial one-year period, with the possibility of four additional one-year option periods, to maintain an uninterrupted supply of these essential medications. The estimated annual requirements detail various dosages and package sizes, with total usage ranging from 2,008 to 118,764 bottles depending on the item. The solicitation is expected to be released around December 18, 2025, with a closing date of January 8, 2026; interested parties should direct inquiries to Ray Roldan at Raymond.Roldan@va.gov or call 708-786-4930.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.
    DLA MedSurg Prime Vendor Gen VI
    Dept Of Defense
    The Defense Logistics Agency (DLA) is seeking proposals for the Medical Surgical Prime Vendor (Med/Surg PV) Program, which aims to provide a comprehensive range of medical and surgical supplies across three Global Regions: North, South, and West. This procurement involves awarding Firm Fixed-Price Indefinite Delivery/Indefinite Quantity (IDIQ) contracts for both Primary and Backup Prime Vendors, facilitating routine ordering and contingency support for various military and federal healthcare facilities. The program is critical for ensuring the availability of essential medical supplies and equipment, supporting the operational readiness of Medical Treatment Facilities (MTFs) and clinics worldwide. Interested vendors must submit their proposals electronically via the DLA Internet Bid Board System (DIBBS) by January 8, 2026, at 3:00 PM Local Philadelphia Time, and can direct inquiries to Beatrice Lopez-Pollard at beatrice.lopez-pollard@dla.mil or Joshua Tankel at Joshua.Tankel@dla.mil.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency (DHA), is soliciting quotes for a Blanket Purchase Agreement (BPA) and an Additional Discount Program (ADP) for pharmaceutical agents to be included in the DoD Uniform Formulary (UF). This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on oncological agents for myelofibrosis and antihemophilic agents, with evaluations based on clinical and cost-effectiveness. Interested vendors must submit their quotes by January 16, 2026, with a pre-quotation teleconference scheduled for November 20, 2025. For further inquiries, contact Tracy Banks at tracy.e.banks2.civ@health.mil or Stephanie Erpelding at stephanie.j.erpelding.civ@health.mil.